Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly, Anthem Singing Same Tune On Value-Based Pricing, Communication Policy

This article was originally published in RPM Report

Executive Summary

“Project Indy” offers a joint manufacturer/payor perspective on how to enable value based pricing. It also sounds like a potential proposal to CMS to volunteer for a pilot project.

You may also be interested in...



HHS Nominee Azar: Great News For Industry But ACA Reform Will Be Priority

Insurance practices are a big driver of drug pricing problems, according to Azar, a former Lilly exec who spent six years at HHS under George W. Bush, providing him valuable experience in department operations.

Value-Based Contracts: Relief From Regulatory Barriers In Sight?

Novartis CEO Jimenez suggests Trump Administration may help remove regulatory barriers to US outcome-based contracting between manufacturers and payers; Duke Margolis Center for Health Policy plans policy initiative to promote value-based purchasing for drugs, medical devices and gene therapy.

Lilly BioMedicines Head Ricks Tasked With Overseeing Growth Phase As Next CEO

Long-time CEO John Lechleiter, who led the company through a challenging period of enormous patent expirations, will step down at year's end.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS079899

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel